Glutathione: What the Evidence Actually Shows

The lightening mechanism is real and reasonably well described: glutathione inhibits tyrosinase and pushes melanin synthesis toward lighter pheomelanin rather than darker eumelanin. What is not established is that putting glutathione into a vein does that job better than swallowing it, or does it at all. That is a genuine open question rather than a rhetorical one, because glutathione taken by mouth is broken down and reassembled rather than absorbed intact, which is the argument sellers use for injecting it — and it is an argument, not a finding. The trials that measured skin pigment and found a change measured it after capsules and after cream. No randomized trial has compared an injection against either, or against placebo, for skin color. The antioxidant and detoxification claims sit on even less: glutathione's role inside the cell is not in doubt, but no trial has shown that raising it from outside changes how a healthy person feels.^2,3

Restricting a PubMed search for glutathione and skin lightening to the randomized-controlled-trial publication type returns five records, and reading them is more useful than counting them. Two are not about glutathione as a treatment at all — they test multi-plant oral supplements and merely measure a glutathione enzyme as a marker. The three real ones are a 2012 trial of oral capsules at 500 mg a day for four weeks in 60 medical students, which found melanin indices fell at all six measured sites and significantly more than placebo at two of them; a 2021 trial in 46 participants comparing topical and oral glutathione, separately and combined; and a 2022 trial of an oral L-cystine and glutathione combination in 124 women over 12 weeks. Capsules, lotion, capsules. For the injected route, the randomized record is a single 2009 pilot: 21 people with Parkinson's disease given intravenous glutathione at 1,400 mg three times a week for four weeks or placebo, in which the drug was well tolerated and there was no significant difference in Parkinson's rating scores. A 2016 review that searched the medical literature for glutathione used for lightening reached the same conclusion from the other direction — the controlled trials it found were capsules in 60 patients and a 2% glutathione disulphide lotion in 30, and no study reported long-term intravenous use at all.^1,2,3,4

There is no established dose for injected glutathione, because there is no trial that established one for anything a consumer buys it for. The single randomized injected-route study used 1,400 mg intravenously three times a week for four weeks in Parkinson's disease, and it did not separate a treatment effect from placebo. The oral trials used their own numbers for their own route — 500 mg a day for four weeks in one, 250 mg of reduced glutathione alone or with 500 mg of L-cystine daily for 12 weeks in another — and those figures do not transfer to a syringe. What is sold instead ranges widely in strength and schedule, and the doses that appear in the FDA's compounding alert are worth knowing for scale rather than as guidance: one clinic gave 1,400 mg intravenously and another 2,400 mg, both at 200 mg per milliliter. This page reports what studies assigned. It is not a protocol, and anyone considering an infusion should be asking a clinician who knows their history.^1,3

The randomized safety base for injected glutathione is one four-week pilot in 21 people with Parkinson's disease, in which it was well tolerated with adverse events similar to placebo. That is a thin foundation, and the 2016 review that went looking for a thicker one concluded the same: most trials reported no or minimal adverse effects, but all of them lasted only a few doses or a few weeks, and no study reported long-term intravenous use. What the record does contain is harm from the compounded product rather than from the molecule. The FDA's June 2019 compounding alert describes seven patients at one outpatient clinic who received 1,400 mg intravenously and within minutes developed nausea, vomiting, lightheadedness, chills, body aches and sneezing, one of them with low blood pressure and difficulty breathing severe enough for hospital transfer; a second report described a patient admitted for suspected bloodstream infection after a 2,400 mg infusion. FDA laboratories found excessive bacterial endotoxin in every sample tested, some at five times the appropriate limit, in powder the manufacturer confirmed was only marketed for use in dietary supplements. A 2025 case report describes a previously healthy woman who collapsed within an hour of a high-dose glutathione infusion given for skin lightening, presenting with shock, a temperature above 41 degrees, acute liver injury and disordered clotting. She recovered fully with supportive care. None of that is an argument that glutathione itself is toxic. It is an argument that the thing being injected is only as safe as the pharmacy that made it.^2,5